Saturday, October 31, 2026

Nike Stock Jumps 5% So Far On Monday, Outperforms Market

ViaNews Editorial Team

December 21, 2020

Nike Stock Jumps 5%  So Far On Monday, Outperforms Market

Shares of Nike rose 5.04% to $144.20 at 12:13 EST on Monday, following yesterday's downward trend. The New York Stock Exchange is dropping 1.52% to $14,247.50, following yesterday's downward trend, This seems, up to now, an all-around rough trend exchanging session today.

Nike's last close was $137.28, 1.61% under its 52-week high of $146.52.

News about Nike today

Tesla, Zoom, Nike: what to watch when the stock market opens today. According to today's article on The Wall Street Journal, "- Nike shares rose 3% in offhours trading. "

Stocks making the biggest moves in the premarket: Tesla, Nike, JPMorgan chase & more. According to today's article on CNBC, "Nike (NKE) - Nike reported quarterly profit of 78 cents per share, 16 cents a share above estimates. "

Nike's Sales

Nike's sales growth is 6.9% for the current quarter and 61.6% for the next. The company's growth estimates for the present quarter and the next is 41.5% and 211.8%, respectively.

Nike's Revenue

Year-on-year quarterly revenue growth grew by 8.9%, now sitting on 38.25B for the twelve trailing months.

Nike's Stock Yearly Top and Bottom Value

Nike's stock is valued at $144.20 at 12:13 EST, under its 52-week high of $146.52 and way higher than its 52-week low of $60.00.

Nike's Moving Average

Nike's value is higher than its 50-day moving average of $133.32 and way higher than its 200-day moving average of $115.82.

Previous days news about Nike

Nike, inc. reports fiscal 2021 second quarter results. According to Business Insider on Fri Dec 18, "Our second quarter revenue performance was impacted by strong Nike Brand digital growth of 84 percent, offset by lower revenue in our wholesale business and NIKE-owned stores. "

Nike inc reports advance in Q2 bottom line. According to Business Insider on Fri Dec 18, "Nike Inc (NKE) revealed earnings for its second quarter that rose from last year.", "Nike Inc earnings at a glance:"

Nike gains after China and e-commerce fuel return to growth. According to Bloomberg Quint on Fri Dec 18, "Over 90% of Nike-owned stores are open today, and inventory levels were down 1.8% from the prior year, the company said.", "Getting rid of excess inventory also has required Nike to dial up its promotions, and that's weighed on its gross margin. "

Nike stock moves toward record after earnings show return to sales growth. According to MarketWatch on Fri Dec 18, "Nike stock closed at a record high Thursday of $140.50 and reached an intraday record of $141.14 in Friday's regular session before falling to a daily decline of 2.3% at $137.28. ", "Sales grew 7% to $11.2 billion from $10.33 billion in the same quarter a year ago, after Nike reported year-over-year sales declines in the previous two quarters, as the COVID-19 pandemic affected its operations. "

Nike powers through pandemic with digital push. According to The Wall Street Journal on Fri Dec 18, "The strong sales from Nike's websites and mobile apps-along with strong demand in China-helped the company log overall sales gains and higher profits than the year-ago period.", "He said the latest results reflect the strength of Nike's strategy and that he was optimistic about the Covid-19 vaccine."

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com